Supplementary Materials

The PDF file includes:

  • Fig. S1. Effect of crizotinib and TAE684 on NB1 cells and experimental workflow.
  • Fig. S2. Quality control for ALK interactome, phosphoproteome, and proteome data.
  • Fig. S3. Volcano plot representation of ALK phosphotyrosine interactome data.
  • Fig. S4. Phosphoproteomics analysis of pathway regulation and sequence motif enrichment analysis.
  • Fig. S5. Differential responses to LDK378, lorlatinib, U0126, and LY294002 in ALK mutant cell lines.
  • Fig. S6. Effects of dasatinib and KD025 treatment alone and in combination with LDK378.
  • Fig. S7. Analysis of signaling changes upon siRNA depletion of ALK or lorlatinib treatment in NB1 cells.
  • Fig. S8. Gene expression data for ALK, IRS2, and FOXO3 in various cancer cell lines.
  • Fig. S9. Effects of IRS2 depletion in NB cells.
  • Legends for data files S1 to S5

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data File S1 (Microsoft Excel format). Summary of ALK interactome data from NB1 cells treated with crizotinib, TAE684, and LDK378 for 30 min.
  • Data File S2 (Microsoft Excel format). Summary of ALK and IRS2 phosphotyrosine interactome data.
  • Data File S3 (Microsoft Excel format). Summary of phosphoproteomics data from NB1 cells treated with crizotinib, TAE684, and LDK378 for 30 min.
  • Data File S4 (Microsoft Excel format). Summary of NB1 cell line proteome data.
  • Data File S5 (Microsoft Excel format). Summary of phosphoproteomics data by TMT 11-plex analysis upon siRNA depletion of ALK or ALK inhibition with low- and high-dose lorlatinib in NB1 cells.